Skip to main content
main-content

SGLT2 inhibitors


Browse the latest news, expert commentary, and educational content on the SGLT2 inhibitor medication class.


Highlights

04-04-2022 | Dapagliflozin | News

Phase 3 trial supports dapagliflozin in young people with type 2 diabetes

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.

02-03-2022 | Empagliflozin | Video

EMPULSE: The ‘missing link’ for empagliflozin in heart failure

Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.

28-02-2022 | Canagliflozin | News

Virtual CHIEF-HF trial supports canagliflozin in heart failure

The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.

More on SGLT2 inhibitors

SGLT2 inhibitors and finerenone for kidney disease treatment

Ian de Boer joins Amrit Lamba to discuss how these medications will influence the treatment of kidney disease in people with DKD.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.